Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT Abstract #1944

Introduction: In external beam radiotherapy it has been well established that improved tissue O2 increases therapy efficacy, likely mediated by O2 derived free radicals. Additionally, emerging evidence suggests immuno-stimulatory effects of radiotherapy through activation of lymphocytes.
Aim(s): In PRRT the relevance of tissue O2 and immuno-stimulation have not been evaluated to date. Therefore, we compared baseline hematology parameters with PRRT efficacy.
Materials and methods: 56 patients with metastasized, progressive and DOTATOC uptake positive NET were treated with 177Lu-DOTATOC. Patients received on average 2.1 (range 1 – 4) cycles of 7.0 GBq every 3 months. Efficacy was analyzed with RECIST 1.1. and classified as complete response, partial response, stable disease or progressive disease and correlated with baseline Hb, erythrocytes, leukocytes, lymphocytes, neutrophils and platelets. Kruskal-Wallis test was used to detect significant differences.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Dr. Cornelis van Echteld

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT
#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years
Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Harshad Kulkarni
Keywords: PRRT, Survival, PET/CT
#2236 Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting
Introduction: Carcinoid syndrome (CS) is frequent in patients with neuroendocrine neoplasia of the small bowel and limits quality of life and may influence prognosis compared to patients with non-functional neuroendocrine neoplasia.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Robert Fijalkowski
#27 Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients
Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Dieter Hörsch
Keywords: PRRT, TACE
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
Authors: Aberle S, Benz M, Grokovski R, Christ E, ...